Search

Copyright of Journal of Harran University Medical Faculty / Harran Üniversitesi Tıp Fakültesi Dergisi is the property of Harran University Medical Faculty and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

To present two cases of placenta percreta which were treated with conservative management in our clinic. Two cases of retained placenta percreta are presented. Treatment was failed in the first case because of haemorrhage. The second one was treated successfully with the procedures which consisted of caesarean section with midline abdominal and classic incision in the uterine fundus, internal iliac artery ligation, prophylactic broad-spectrum antibiotic treatment, suppression of menstrual cycle, use of methotrexate until the achievement of rapid downtrend of human chorionic gonadotropin, and monitoring the patient until spontan expulsion or resorbtion of placenta. It may be better to treat the cases of placenta percreta with conservative management, if the patients are hemodynamically stable and desirable for future fertility. [ABSTRACT FROM AUTHOR]

Cervical cancer is the second common form of cancer in women after the breast cancer. Each year, approximately 500,000 new cases of cancer worldwide recognize and nearly half of them die. After detection of the relationship between cervical cancer and human papilloma virus (HPV) studies both the prophylactic and therapeutic vaccine was accelerated. In 2006, a quadrivalent HPV 6-11-16-18 vaccine containing L1 capsid antigen, in 2007, a bivalent vaccine containing HPV 16-18 L1 capsid antigen were released. HPV vaccines produce protect antibodies against four types of HPV. Vaccines are safe and well tolerated, and leading lesions of cervical cancer and cervical cancer can be prevented. HPV vaccines are recommended in the possible range of 9-26 years, and especially before the first sexual contact. Although the prophylactic vaccine protective against cervical cancer, cervical cancer screening should be continued after vaccinations. [ABSTRACT FROM AUTHOR]